GSK Signs US$1.5 B ADC Licensing Pact with Hansoh Pharma

By Lalit Mishra

Pharma Deals Review: Vol 2023 Issue 10 (Table of Contents)

Published: 27 Oct-2023

DOI: 10.3833/pdr.v2023.i10.2827     ISSN: 1756-7874

Section: Licensing



In a significant move towards bolstering its oncology portfolio, GSK has entered into an exclusive license agreement with Hansoh Pharma for HS-20089, a B7-H4 targeted antibody-drug conjugate (ADC) currently in Phase I clinical trials in China for the treatment of ovarian and endometrial cancer...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details